Asthma associated morbidity, disability and rates of premature death continue to increase. Asthma is now recognized as a disease of airway inflammation in which airway eosinophilia is a prominent histologic feature. Eosinophils in asthmatic airways are activated and release preformed toxic cationic granule proteins; they generate oxidative products, lipid mediators and pro-inflammatory cytokines that can induce airway hyperresponsiveness which is the cardinal physiological feature of asthma. The importance of airway eosinophilia to asthma is suggested by the observation that the efficacy of steroids in the treatment of asthma is associated with the resolution of airway eosinophilia. Clarifying the mechanisms that recruit eosinophils into the airway has the potential to identify novel therapeutic targets relevant to allergic disease. Modulation of the eosinophilic inflammatory response might result in more effective immunotherapy without the toxicity associated with corticosteroid therapy. Our long term goals are to understand the role of eotaxin in airway inflammation and eosinophil tracking, which may lead to the development of novel asthma therapies. We propose to determine if eotaxin is a sufficient and necessary stimulus for eosinophil homing and airway hyperresponsiveness in murine models of allergic airways disease. These 'proof of concept' studies in the mouse, aimed at determining if blocking eotaxin function is a viable approach for a novel asthma therapy, will be coupled to human studies aimed at establishing a link between eotaxin and asthma. We specifically propose: (1) To characterize the biological properties of eotaxin in-vitro and in- vivo, including studying the role of eotaxin in mediating nasal and airway eosinophilia and bronchial hyperreactivity by administering purified, active, recombinant eotaxin to mice. (2) To determine if neutralizing eotaxin will prevent eosinophil migration and airway hyperactivity by generating a neutralizing hamster anti-mouse eotaxin monoclonal antibody. (3) To correlate the expression of eotaxin mRNA and protein in the lungs and bronchoalveolar lavage fluid following allergen challenge in allergic patients with and without asthma. (4) To complete the characterization of the binding and signaling properties of the eotaxin receptor and to determine if it and/or a novel eosinophil seven transmembrane-spanning receptor (ESTR) is involved with the expression of the asthma phenotype in humans. This work will lead to a greater understanding of the importance of eotaxin and eosinophil receptors in asthma. In addition, we hope this work will elucidate the role of the eosinophil in inducing bronchial hyperreactivity in allergic diseases, as well as suggest potential targets for novel therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040618-03
Application #
2856055
Study Section
Lung Biology and Pathology Study Section (LBPA)
Program Officer
Adams, Ken
Project Start
1997-01-01
Project End
2001-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Sokol, Caroline L; Camire, Ryan B; Jones, Michael C et al. (2018) The Chemokine Receptor CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to Initiate the Allergic Immune Response. Immunity 49:449-463.e6
Rahimi, Rod A; Luster, Andrew D (2018) Chemokines: Critical Regulators of Memory T Cell Development, Maintenance, and Function. Adv Immunol 138:71-98
Kelly, Vanessa J; Winkler, Tilo; Venegas, Jose G et al. (2015) Allergic Non-Asthmatic Adults Have Regional Pulmonary Responses to Segmental Allergen Challenge. PLoS One 10:e0143976
Severa, Martina; Islam, Sabina A; Waggoner, Stephen N et al. (2014) The transcriptional repressor BLIMP1 curbs host defenses by suppressing expression of the chemokine CCL8. J Immunol 192:2291-304
Griffith, Jason W; Luster, Andrew D (2013) Targeting cells in motion: migrating toward improved therapies. Eur J Immunol 43:1430-5
Oyoshi, Michiko K; He, Rui; Li, Yitang et al. (2012) Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. Immunity 37:747-58
Harris, R Scott; Venegas, José G; Wongviriyawong, Chanikarn et al. (2011) 18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma. J Nucl Med 52:1713-20
Mikhak, Zamaneh; Fukui, Mieko; Farsidjani, Alireza et al. (2009) Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. J Allergy Clin Immunol 123:67-73.e3
Medoff, Benjamin D; Okamoto, Yoshihisa; Leyton, Patricio et al. (2009) Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 41:397-406
Medoff, Benjamin D; Seung, Edward; Hong, Sandra et al. (2009) CD11b+ myeloid cells are the key mediators of Th2 cell homing into the airway in allergic inflammation. J Immunol 182:623-35

Showing the most recent 10 out of 41 publications